Impact of UGT1A1 gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS clinical trials group study A5202

Heather J. Ribaudo, Eric S. Daar, Camlin Tierney, Gene D. Morse, Katie Mollan, Paul E. Sax, Margaret A. Fischl, Ann C. Collier, David W. Haas

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

The UGT1A1*28 variant has been associated with hyperbilirubinemia and atazanavir discontinuation. Protocol A5202 randomly assigned human immunodeficiency virus type 1 (HIV-1)-infected patients to receive atazanavir/ritonavir (atazanavir/r) or efavirenz, with tenofovir/emtricitabine or abacavir/lamivudine. A total of 646 atazanavir/r recipients were evaluable for UGT1A1. Homozygosity for *28/*28 was present in 8% of whites, 24% of blacks, and 18% of Hispanics and was associated with increased bilirubin concentrations. There was an association between *28/*28 and increased atazanavir/r discontinuation among Hispanic participants (P =. 005) but not among white or black participants (P =. 79 and P =. 46, respectively). The positive predictive value of 28*/28* for atazanavir/r discontinuation among Hispanic participants was only 32% (95% confidence interval, 16%-52%).

Original languageEnglish (US)
Pages (from-to)420-425
Number of pages6
JournalJournal of Infectious Diseases
Volume207
Issue number3
DOIs
StatePublished - Feb 1 2013

    Fingerprint

Keywords

  • atazanavir
  • Gilbert syndrome
  • HIV therapy
  • pharmacogenetics
  • UGT1A1

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Ribaudo, H. J., Daar, E. S., Tierney, C., Morse, G. D., Mollan, K., Sax, P. E., Fischl, M. A., Collier, A. C., & Haas, D. W. (2013). Impact of UGT1A1 gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS clinical trials group study A5202. Journal of Infectious Diseases, 207(3), 420-425. https://doi.org/10.1093/infdis/jis690